Overview


The company is now raising $10M in the second round of Regulation A+ crowdfunding to support the growth of its portfolio of brands, develop new exciting products and pursue acquisition opportunities. All of this will provide our customers with safe and effective solutions to products and services that historically overuse toxic synthetic chemicals and addictive pharmaceutical products.

INVEST NOWView Our Offering Circular

YEAR FOUNDED

2014

RAISED TO DATE

$1M+

INVESTORS

400

MODEL

Portfolio

CURRENT PRICE PER SHARE

$.80

CURRENT MINIMUM INVESTMENT

$420

INDUSTRY

Pest Control, Healthcare, Cannabis

PATH TO LIQUIDITY

IPO

Opportunity

The Problem

Nearly everyone on this planet is exposed to pesticides or has taken a pain relief pill, and science has proven the long-term health complications and diseases that can happen as a result. Yet, too few people are aware that alternative, Eco-friendly products, and methods exist in the market that do a similar job, with the same efficacy, but with zero negative impact on oneself or the environment.

Reports estimate that in the United States alone over 20 billion pounds of pesticides have been sprayed on our properties and food in just the last 20 years. Globally in the same timespan, this industry has generated over $1 Trillion in revenues. So, why are we all so exposed?

pesticide-graph

Millions of Pounds of Pesticides
Continue to be Sprayed Each Year

Historically, the use of synthetic chemicals in all of our food, drugs, products, and industries has been controlled by a small group of very large and powerful international corporations. These corporations hold patents and spend millions of dollars lobbying governments all over the world to make sure their products are deemed safe for use, even though the long-term effects from exposure have been proven to be unhealthful and dangerous.

Most of these synthetic chemicals contain strong toxic/poisonous chemicals with proven long-lasting, devastating carcinogenic effects. These compounds can take generations to become nascent in the environment. As more chemicals are sprayed or used in products, the build-up just keeps compounding the pollution that harms the environment.

We all know a family that has been impacted by the Opioid Public Health crisis the Pharmaceutical conglomerates have directly caused in this country by using similar unethical tactics of lobbying to get their addictive drugs in the hands of as many everyday Americans as possible. These addictive drugs that have been marketed for the use of everyday pain when science clearly proves the addictive nature of the chemicals used to make them. For a person born in 2017 the odds of dying from an Opioid Overdose is now higher than dying in a car accident.

Chemicals from plastics and pesticides are now beginning to be found in our groundwater and public drinking water supplies for the first time. No wonder numerous studies are now linking diseases such as Parkinson’s disease, asthma, cancer and reproductive dysfunction to chemical pesticides.

Opioid-Chart

29% OF ALL PEOPLE WHO ARE PRESCRIBED OPIOIDS END UP MISUSING THEM AND 12% OF  ALL PEOPLE PRESCRIBED OPOIDS BECOME ADDICTED

The Med-X Solution

Med-X, Inc. has developed multiple all-natural plant-based brands of products that solve the same everyday issues people have been using chemicals to solve. Med-X is able to sell these products into the homes of everyday Americans through our partnerships with major retail and healthcare distributors as well as the leading international professional pest control distributors. The company is constantly marketing and educating the public about the dangers we face while at the same time offering real, proven effective, safe solutions. 

Through targeted marketing, national and international distribution venues and exposure through our media divisions, our high margin proprietary products are cutting through the noise and getting mainstream attention and sell-through. Med-X is also on the cutting edge of green product development by introducing new cannabis/hemp topical and supplement products that will also become available to consumers in the future.

Our Mission

We would love to tell you that our green solution products and services will bring down big chemical and big pharma., but let’s be real, that is not going to happen. The point of this mission, in fact, is more about balance, transparency, and responsibility. Our goal here is to simply offer alternatives in markets that frankly have never embraced safe and effective natural options and as you are aware, our thinking and products are beginning to resonate.

Safe Is The New Normal

We are at the forefront of providing safer alternatives to big chemical and big pharma which will allow them to become more accountable. The consumer is demanding it. Times have changed. If you can offer a person two solutions to a problem, one is a chemical solution and one is a green solution, most Americans will now choose the green option as long as it has similar results. It is proven most Americans will actually pay substantially more for a safer option. Thankfully, the products Med-X produces, fall in line with middle America value and the company has sourced product ingredients and have focused on low-cost manufacturing techniques that enable the company to offer these products at favorable costs to consumers while holding higher margins for stakeholders.

In the past, there were little or no options for a homeowner to choose an effective green pesticide to be used in their home. Likewise, there were limited safe, drug-free options for truly relieving a migraine headache or everyday chronic pain. Now there are multiple options being offered by our Med-X Divisions and more that are in final development by Med-X scientists, doctors, and formulators. These products are proven effective in clinical trials and many are already in national and international distribution channels with sell-through driving growth.

products-group

Making a Difference, One Community at a Time.

Med-X, Inc. is an innovator and leader in developing all-natural and alternative solutions to the outdated poisonous chemicals and harmful pharmaceutical products, often used in pest control and pain management. Med-X incorporates best-in-class science, research and technology for manufacturing and service capabilities across pest control, pain management, aromatherapy, by primarily utilizing essential oil product development.

The company’s sales are represented by multiple commercial sales verticals and third-party service providers managed through various domestic and international distribution partners. Retail sales are currently conducted by over-the-counter pharmacy retailers and various e-commerce service providers. Med-X is also focused on educating the public by supporting its digital media platforms of The Marijuana Times and The National Investor Network.

Our Brands

Med-X has built a portfolio of high margin commercial and consumer product brands as well as pest control services. These proven brands help drive the company’s current revenue. This portfolio strategy gives the company flexibility and power to scale up operations, and raise revenues in any sector by acquiring other like-minded brands who fit the company mission and would like the opportunity to grow together. The company is already in talks with several small to medium-sized companies who have shown interest in being a part of a bigger green movement.

The Med-X management team is motivated to continue to grow revenue and raise the capital needed to take the company public on a national exchange. Med-X has reserved the Nasdaq ticker symbol, (MXRX) and plans to offer its investors liquidity by entering the public market in the future.




nature-cide-logo

The entire Nature-Cide line of products has 10 years of research and development behind them. All of these products have been proven effective in the field by licensed pest management professionals as well as by conducting third party laboratory efficacy tests. All of these products are registered in the 39 states that require EPA registration. These products are currently being utilized in major commercial and residential use nation wide in mainstream pest control, hospitality and agriculture. For SDS, Ingredients and Label information please visit each product product page.

 

thermal-aid-logo

Thermal-Aid all-natural products are clinically proven and patented therapeutic heating/cooling modality designed explicitly for the medical field, to reduce swelling and relieve various pain issues. Thermal-Aid products cover a wide variety of needs for patients in all age groups for a gamut of ailments including but not limited to arthritis, fibromyalgia, multiple sclerosis, migraines, back pain, and muscle aches. Thermal-Aid products can be found in various OTC pharmacy outlets and qualify for patient insurance reimbursement and FSA programs throughout the United States.

 

malibu-brands-logo

Malibu Brands is a premium, homeopathic lifestyle brand.  Malibu Brands' first product is the Pacific Pain Relief Cream, which is a proven, natural topical analgesic cream for the temporary relief of various pains including arthritis, joint, muscle, headache, and migraine pain. Malibu Brands is working to expand its product footprint with multiple products in development including a pain cream that utilizes hemp / CBD as an ingredient. Additionally, the Malibu Brands division is planning to embark on designing a unique clothing line that uses alternative sustainable materials such as hemp fiber and bamboo as they become readily available.

 

mj-times-logo

The Marijuana Times is a thought leader in the cannabis space, especially with exposing certain blemished areas of the industry, such as the widespread unregulated chemical use by cultivators and the dangerous health impact of consuming products with high levels of synthetic chemicals. The Marijuana Times publishes content on a daily basis via its a website, IOS news application, audio podcast and daily YouTube news show. The publication is a verified Google News and Apple News, publisher.

image (1)

nin-logo

The National Investor Network is a hub for everyday investors to gather resources and information in regards to companies raising capital using public or private equity.  It serves as a portal with an extensive information base of companies and executives who are publicly raising capital or trading securities. This venue will be positioned to assist Med-X and other private and public companies with information dissemination to assist in their pursuits.

image-1

Going Forward Strategy

Nature-Cide Products & Services

Expand market positioning with commercial advertising and expanded distribution of the Nature-Cide product lines for continued sale in Commercial Pest Control, Hospitality, Janitorial, Transportation, Housing Authorities, School Districts, Turf-Care and Agriculture including cannabis cultivation. We will also be preparing several Nature-Cide Ready to Use SKUs for consumer use to be primarily positioned in various Big Box retail.

The Nature-Cide service division plans to continue to grow its footprint in the Greater Los Angeles area as the management team continues to aggressively push to increase revenues and market share by acquiring existing pest control service companies and injecting the Nature-Cide products and Integrated Pest Management model into their existing book of business.

Thermal-Aid and Malibu Brands Products

Expand the market presence of Thermal-Aid in Pain Management sectors including insurance coverage segments for Physical Therapy, Flexible Spending, and Patient Care while continuing the expansion of its retail footprint within the OTC Pharmacy space.

Continue the placement of all products that fit within consumer retail with e-commerce expansion, including positioning the Malibu Brands assortment of products into the same position.

Product Positioning

National Pest Control And Healthcare Distribution

Nature-Cide is being used by a growing network of commercial customers including licensed pest control companies, like nationally positioned PestMaster Services, which provides pest control services in fourteen states. Nature-Cide currently supplies Univar Solutions, Target Specialty Products
and its parent company “Rentokil Initial” in various regions including Asia and India.

The company plans to continue aggressively marketing within the Pest Control, Hospitality, Transportation, Agriculture, and Janitorial supply markets, while also pursuing the implementation of Nature-Cide in state and federal facilities throughout various regions in the United States.

pest-control-distribution-map

Market Overviews

Pain Management

The global pain management drug market is estimated to grow from $36.6 billion in 2014 to $44.3 billion by 2020. Pain is a distressing sensory and emotional feeling, which occurs due to tissue damage or illness. Various diseases, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer can cause pain. The duration of the pain varies from short-term known as acute pain to long-term referred to as chronic pain. Traditionally, the management of pain involves the reduction or treatment of pain using a particular set of drugs. Currently, 166 people die each day from an overdose by abusing prescription opiate pain medication. The need to improve service quality and safety for patients is expected to provide an impetus for growth in the pain management solution market.


Pest Management

The global insect pest control market is projected to grow from $12.4 billion in 2016 to $17.3 billion by 2022, according to research firm Markets and Markets. The insect pest control market is driven by government regulations on food hygiene, public health, environmental health, and growing public awareness. The need to improve service quality for customers
is expected to provide an impetus for growth in innovative pest control solutions. Lack of skilled technicians and delayed regulatory approval process for chemical products in different applications (such as residential, commercial, and industrial areas) have been considered restraining factors for the market and offer opportunities for products that fall under the less regulated FIFRA 25(b) Minimum Risk Pesticide category.

pest-control-graph@2x

 

pain-management-graph@2x

 

Cannabis Products And Services

The Med-X management team is a major proponent of the legalization of medical cannabis on a federal level. As a member of the pest control community in the cannabis industry, the team hopes to expand its footprint in this emerging market by not only supplying pest control products to cannabis and hemp cultivators but also legally participating in the cultivation and manufacturing of hemp and cannabis products.

Company management holds licenses for various types of applications for Pest Control and is trained and proficient in several types of cultivation, including hemp and cannabis. Management is proficient in supercritical CO2 extraction of all types of essential oils, and if and when the Federal Government eases rules and regulations on hemp and medical cannabis cultivation, sales, manufacturing and transportation, the company is positioned to enter cultivation and manufacturing of all types of hemp and medical cannabis-related products.

 

Cannabis Market Overview

The legalization of recreational/medical cannabis is taking over the United States. Multiple states have seen massive tax gains from legalizing recreational use while medical system states continue to be a model for other states around the country. More than half of the states in the U.S. have some medical marijuana legislation.

cannabis-market-map

Expected Revenues Are Too Big To Ignore

As more states legalize medical and recreational cannabis, the demand for Med-X’s quality products is growing. Innovation is where Med-X excels, and Med-X consumer-ready products support the expansion of the industry.

State by state, new requirements for contaminant testing and product potency are affecting cultivators who handle pests and molds with harmful and toxic treatments of the past. As laws remove harmful and poisonous pesticides from the cultivation facilities and require nontoxic treatments, Nature-Cide is positioned to become an industry standard for organic pest
control management.

cannabis-revenue-graph




Why Invest?

There is a very large demand for new effective all-natural solutions in both mainstream pest control and in the world of pharmaceuticals. The potential for the investor to prosper in these markets is there. These markets are long overdue for new ideas and innovations and opportunities to invest in these markets is rare and difficult to come by for the working-class American.

An investment in Med-X, is the opportunity to get in on the ground floor of a company that is already disrupting these markets with green options. We know that a larger portion of the market shares in these industries must move to the safer, greener side and we are sitting perfectly to address the needs of the markets as consumers continue to demand alternative options.

INVEST NOW



  • Traction

  • Growing Revenue

  • Distribution

  • Hemp & Cannabis

  • Make A Difference

  • Portfolio Model

  • In-House Media

  • Path To Liquidity

History

company-history

Our Team

 
david-toomey

Dr. David Toomey

CEO AND DIRECTOR

Dr. David Toomey’s professional life has been spent as a family physician for more than 24 years and a Hospice Medical Director for the last decade. Over his many years as a physician, Dr. Toomey has also worked as a clinical investigator developing and testing, in clinical trials for multiple companies including major pharmaceutical companies.

matthew-mills

Matthew A. Mills

COO AND PRESIDENT

COO and President of Med-X, Inc. since inception, Matthew Mills is the company’s visionary, he utilizes and implements his vast experience and knowledge in product development, operations, business development, manufacturing, marketing and crowdfunding to position the company for short-term and long-term growth.

Ronald-Tchorzewski

Ronald J. Tchorzewski

CFO, DIRECTOR

CFO and Director Med-X, Inc. since inception, Ron Tchorzewski has over thirty-five years of experience in financial accounting for start-up and development companies, as well as reporting for publicly held companies from Silicon Valley and beyond. His chief financial officer level support, including business plan development, capital structure, and day-to-day accounting experience positions Med-X, Inc. for financial success.

jennifer-mills

Jennifer Mills

VICE PRESIDENT, CORPORATE SECRETARY, DIRECTOR

Jennifer Mills has been the Executive Vice President, Director and corporate secretary of Med-X, Inc. since its inception, Jennifer Mills has worked for multiple companies in her career as a high-level accounting liaison as well as in Human Resources and project management.

nick-phillips

Nick Phillips

VICE PRESIDENT, EDITOR-IN-CHIEF

Began his career in the Hollywood entertainment world and moved into digital marketing for multiple products in Los Angeles, which led him to The Marijuana Times. He drives The Marijuana Times digital magazine to fill a void in the reporting of the cannabis industry by providing a voice, education and news about the cannabis community. His skill set coupled with his dedication and attention to detail gives The Marijuana Times the leading edge in the industry.

allan-kurtz

Dr. Allan Kurtz

DIRECTOR

Dr. Allan Kurtz is board-certified in internal medicine and has owned and operated Allan Kurtz, a Professional Medical Corporation, since 1986. Dr. Kurtz has been the Medical Director of Warner Medical Center and the California Center of Longevity Medicine. He is also a long-time member of the American Osteopathic College of Internal Medicine.

morton-hyson

Dr. Morton Hyson

DIRECTOR

Dr. Morton Hyson is in private practice as a Board-certified Neurologist in Las Vegas, Nevada. He is also a Clinical Assistant Professor at Touro University in San Francisco, California, where he has been educating since September 2000. His professional affiliations include the American Medical Association, the American Academy of Neurology, the American Academy of Neurological and Orthopedic Surgeons, the American Headache Society.

fred-dashiell

Frederick Dashiell, Jr.

DIRECTOR

Mr. Dashiell has held various teaching positions at educational institutions such as Chapman University in Orange, California, University of California at Los Angeles and California Institute of Technology. Mr. Dashiell has also held various positions as a computer scientist as well as a research scientist in the private sector. Mr. Dashiell received a Bachelor of Science degree in physics from the University of North Carolina at Chapel Hill in 1963 and a Ph.D. in mathematics from the University of California at Berkeley in 1973.

Frequently Asked Questions


All Economic Value details, including future projections, employment numbers and or statistics, are sourced from The Marijuana Business Fact Book. Produced by the Marijuana Business Daily. Industry and revenue statistics are sourced from the ArcView Market Research Report.

What is Reg A+ Equity Crowdfunding?

All Economic Value details, including future projections, employment numbers and or statistics, are sourced from The Marijuana Business Fact Book. Produced by the Marijuana Business Daily. Industry and revenue statistics are sourced from the ArcView Market Research Report.

In June 2015, the final Regulation A+ rules under Title IV of the JOBS Act of 2012 became effective, after approval by the Securities and Exchange Commission, paving the way for companies like Med-X, Inc. to raise up to $50 million from both accredited and non-accredited investors.

Med-X, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Updates

11/20/2020

Med-X Inc. COO Matthew Mills:  All Shareholders Need to Get Organized and Get Involved as the Company Growth Plan and Strategy Continues

In this video to all Med-X shareholders, President and COO, Matthew Mills gets up close and personal and discusses how all investors need to be organized and involved in the direction of the Company, as it accelerates into 2021. 

As Matthew discusses the various entities that are aligning with the Company and its multiple divisions, he is reminded of, and shares the past experience of a pathway of a previous public listing, and makes it very clear that ALL shareholders need to make sure their online portal dashboard accounts are in order. 

Additionally, the Company management team and general counsel are preparing and organizing the Company in a manner where a listing on a public exchange could go hand in hand with large scale financing and acquisitions during the process. 

It's very clear to management that agility is everything, and a multitude of options are seemingly presenting themselves from the multiple relationships that are building up around the Company. To reiterate, this is another reason to make sure your stock account is in order. 

Please watch the video before you read the rest of this. 

 

 

As we continue to plan the pathway to a possible listing of the Company on a national stock exchange, we want to make it clear and keep repeating this… 

The New Portal and Investment Gateway has been linked for ease of use for logging into your account, and for making additional investments, as you will see in the link below. 

Please, if you have not gained access to your Investor Dashboard on www.medxinvestor.com, please take the steps to do so. Send an email to info@medx-rx.com if you need help. 

This is a critical time. 

As a shareholder, NOW is the time to get organized. 

NOW is the time to stay very engaged. 

NOW is the time to participate as the Company is in a critical stage of growth.  

Our experience of raising capital from hundreds of investors and taking a company public is extensive and history has taught us that it is the investors who are actively participating, engaged, and are organized in advance are who will benefit most when a possible listing happens. 

Past listings have proved that many shareholders simply missed the boat to maximize the liquidity event because they were not focused, not prepared, unorganized, and not engaged. 

How did this happen?

Shareholders had moved, changed email or phone numbers, and failed to let the company know. 

As the company got closer and eventually listed, the investor relations team was not able to contact them, they never got the letter, call or email and they simply did not know what the company's status was, and missed out on maximizing their investment. 

Do not let this be you. Don’t be late to the party. 

As the Management Team, we will continue to do everything in our power to reach as many of our 3,000+ investors as possible, as we get closer to all the opportunities that lead all of us to achieve our growth goals. 

So once again, please log in and participate!

As Matthew discusses in the video, please be aware of the continued growth of the Company, and what it needs to move forward. Obviously the recent engagement with US Capital Global and Eurasian Capital has Company management working hand in hand with organizing a planned global investment banking marketing roll-out, to support the projected growth and the possible listing of the Company. 

However, continuing the Regulation A+ Crowdfunding that has played a key role in the Company growth thus far, is seemingly far less costly to the Company and could prove beneficial to shareholders before the large scale financiers negotiate deals, which in turn halts the Company's internal fundraising efforts. 

This said, as Matthew explains in the video, that If ALL current shareholders were to invest $2,500 all at once, this self-funded position could allow the Company to skip the step of raising large scale capital, which could allow the Company much better bargaining power, which in many cases, could increase the company’s valuation greatly. 

Management believes that the size of the markets the Company’s divisions are supporting, are in dire need of the types of green scene products we produce and will be for generations to come. 

That said, encouraging investors to continue taking small positions in the Company, could not only be beneficial to the Company but could create even more value to current shareholders as the Company continues on its planned growth path to a market listing.

Your support has positioned this Company with a growing revenue stream, from products you helped create and market!! 

We have the attention of some very large entities on all sides of the business, so your participation has turned into something amazing. 

It's vital and a must that you focus on your account, and recognize the Company's position and keep yourself apprised of current events and communications, so log into your account today! 

Happy Thanksgiving and stay safe, 

The Med-X Team

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

11/10/2020

Over 1,100 Shareholders Have Successfully Accessed Their Med-X Shareholder Dashboard

In this video, COO and President, Matthew Mills updates everyone on the launch of the new shareholder dashboard. 

 

 

The initial launch on Oct. 21st was a success with over 1,100 shareholders successfully verifying and gaining access to their dashboard. 

If you missed the last Update please go to www.medxinvestor.com/#updates and review. If you are reading this from the update page you can see it by scrolling down. 

As a Reminder.

To log Into Your Dashboard: 

VERIFIED USERS: Go to www.medxinvestor.com and click the investor login in button. 

NEW USERS: If you have not registered yet and did not receive the last update please email us at info@medx-rx.com and Nick Philips will resend your Verification email. 

If you are still waiting patiently to get logged in and need a phone call from our staff to help you, please send an email to info@medx-rx.com. Nick will follow up with you and schedule a time to walk you through it over the phone. 

As we explain in the video if you log into your Dashboard and notice an error in the recording of your investments, please do not worry. Please send an email to info@medx-rx.com and we will follow up and get everything corrected for you. We have records on every single individual investment from all 3,000+ shareholders. 

If you wish to invest more money you can always do so by going to www.medxinvestor.com or by logging into your dashboard and clicking the Invest Now button. 

Thanks for your participation, patience, and continued support.

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

10/21/2020

US Capital Global Engages With Med-X, Inc. as Strategic Advisor for 10MM Capital Formation

In this video update President and COO, Matthew Mills announces the engagement with Global Capital Group, Year-to-date Revenue Numbers, and how to access the new Med-X Shareholder Dashboard. 

This update is full of important information so please take the time to read the entire update. 

 

 

Global private financial group, US Capital Global, headquartered in San Francisco engaged by Med-X, Inc., Los Angeles-based green technology manufacturer as a strategic advisor.

SAN FRANCISCO, OCTOBER 2020 – US Capital Global has been retained by Med-X, Inc. (“Med-X”) as its strategic advisor for a $10 million capital formation. 

Med-X intends to use the additional financing to expand three of its natural product divisions, Nature-Cide, Thermal-Aid, and Malibu Brands, which are positioned for international distribution, as well as to further position the company to potentially go public and eventually be listed on a U.S. stock exchange.

Headquartered in Los Angeles, CA, Med-X is an innovator in developing all-natural, eco-friendly alternatives to products containing poisonous chemicals and harmful pharmaceuticals, often used in pest control, pain management, and agriculture. 

Med-X sells its products through leading international pest control distributors and applicators, as well as directly to American homes through partnerships with major retail and healthcare distributors.

Link to Press Release: https://bit.ly/2TfwxUX

----

Revenue Updates

The company has officially surpassed last year’s revenue numbers with 10 weeks still to go before the end of the year. The management team is hopeful we can break the one million dollar revenue mark in 2020. 

Screen Shot 2020-10-22 at 4.20.43 PM

The management team is very excited to share that they have landed one of the largest green pest control service companies, Greenix with over 300 service providers. 

Screen Shot 2020-10-22 at 4.18.26 PM

“To land an account of this size at this time of year is a great achievement and a great sign going into next year,” explained COO, Matthew Mills. “The reputation of Nature-Cide continues to build in the commercial pesticide industry and we are confident it will continue to grow year after year as demand for natural options only gets larger.”

----

Shareholder Dashboard

 The Med-X management team has now made it possible for all Med-X company shareholders to log into a secure dashboard to see your investments in the company. 

The dashboard is designed to act as your place to go to get information about the company like news, updates and to give you a way to update your contact information. 

 Please be patient while we roll this out. With over 3000 investors we know there will be some mistakes. Please let us know if you notice an issue with your account. 

 The most important thing is to get everyone logged in and to confirm your Contact Information. As we get closer and closer to possibly taking the company public it is very important we have your correct contact information. 

If you need to change something in your contact information please click “Request a Change,” on the left sidebar. Please fill out the form with your current information. 

The more organized we are now the smoother things will possibly be in the future, as we expect Broker-Dealers, Market Makers, and Investment bankers to want to have a quick snapshot of our investor base. 

It is very important for the company to have full transparency with all the shareholders so we are all on the same page as we continue to grow. 

To access your Dashboard:

If you are already a Member of the National Investor Network (“NIN”), this login information will work to log yourself into the Dashboard. Just go to www.medxinvestor.com and click the INVESTOR LOGIN button. 

If you are not a Member of NIN, in order to participate with the shareholder dashboard, you must have access to the email you used when you made your investment. 

A verification email was sent on 10/21/2020 to your investment email address. If you do not see the email, please search: “Verify MedX Investor Account” - this email was sent from nick@med-x-rx.com

If you cannot find the email, please contact info@medx-rx.com, and we will attempt to Re-Send the email. 

If you are already a Member of the National Investor Network (“NIN”), you are technically already in the system and just need to log in. These NIN members will not receive a Verification Email because you are already signed up. 

Click the INVESTOR LOGIN button on www.Medxinvestor.com

If you cannot remember your NIN Password, please follow the process of resetting your password. When you do this, it may bounce you to nationalinvestornetwork.com. 

When this happens, open medxinvestor.com in a new tab, and you will now see a Dashboard Link in the upper right-hand corner. 

When inside your dashboard, you will be able to see a snapshot of your investment history as well as access to view all of your individual investments. 

The team has worked with a world-class development team to make sure the system was built with privacy and complete security in mind. All official investment documents are securely stored within the PrimeTrust investment platform and not within the Med-X portal, so rest assured that your information is securely protected.

The only information the company is storing in our secure system is your personal contact information and an unofficial snapshot of each investment. The snapshot includes the date an individual investment was made and the number of shares invested. 

The portal is only open to confirmed and approved shareholders in Med-X, Inc. 

If you have questions about your investments or how to use the portal, Email us at info@medx-rx.com or call 818-527-9966 for more assistance. 

----

These are very exciting times for the company and we look forward to more progress and updates before the end of 2020. 

 Thank you for all of your continued support. 

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

9/16/2020

Med-X Engages with Eurasian Capital to Support Planned Path to IPO

In this video update, COO and President, Matthew Mills discusses a new partnership with Eurasian Capital, LLC., shipping to Southeast Asian countries, and year-to-date revenue updates.

 

 

Progress on the planning of the IPO continues to move forward. We have officially engaged with Eurasian Capital, LLC. Eurasian Capital has a proven track record of handpicking specific high growth companies and supporting their expansion plans by investing and marketing to their network of pension funds, family offices, hedge funds, private equity firms, venture funds, securities analysts (buy-side/sell-side), stockbrokers, and institutional investors.

As Matthew discussed in the video, we are hoping to be able to make another engagement announcement in the coming weeks in regards to a possible partner who is potentially interested in supporting our efforts with an infusion of large-scale capital to possibly help close the current funding rounds and accelerate the plan to an Initial Public Offering. 

We are excited to have such an experienced partner in Eurasian Capital to support the management team on many fronts as well as widely expand our marketing reach. This is another major milestone in the planning process of our IPO. As we continue to build out our team we will continue to update you on planning developments and milestones. 

Several institutions have shown strong interest and it is critical that we do our due diligence and select the right partners, with the right experience and track record to move our plan forward in the best interest for the Company and its shareholders. 

International distribution continues to grow after the release of the Nature-Cide toxicity reports. Singapore, Thailand, and Vietnam Rentokil Initial are expected to begin shipping soon. Nature-Cide negotiations have accelerated within Australia and Mexico, and will hopefully be our next international positioning.  

2020 has turned out to be our best year in the Company's history for digital direct to consumer sales. The ecommerce initiatives we announced in late 2019 have proved successful and we are hopeful the end of the year will be our best Q4 yet. Historically Q4 is our best ecommerce quarter with our Thermal-Aid product lines. This season we were able to bolster our inventory thanks to all of our shareholders' support from earlier in the year and now it is time to reap the benefits going into the holiday season. 

Overall in 2020, we have nearly matched our total 2019 revenue numbers here in the 3rd quarter, even before we reach our historically best sales quarter. Management is hopeful that our 2020 revenue will exceed our expectations. Even during Covid-19 we were able to keep the doors open and grow our business. We are all very proud of that, and very grateful to our investors who helped keep the business moving forward.

With our plan continuing to move forward with an IPO, our focus on growth has never been more important. Our plan cannot happen without the continued support of our shareholders and the team to continue to grow the Company. None of this could or can be possible without the hard work of our team and our shareholders pushing the growth. This is a major talking point when Matthew and the management team are in discussions with institutional investors. Doing an IPO is one thing but supporting the share price with continued growth once we go public is critical, and it remains vital that we continue to fund our growth, before and during the process of entering the public market, so we look attractive to larger institutional players once we begin trading to super size our growth potential.   

We are very thankful and appreciative to all of our shareholders. If you are closely watching Med-X but have not become an investor yet, we ask you to jump on board and invest. If you are one of the over 3,000 shareholders that has already invested, your continued support is greatly appreciated. If you have questions please contact your investor relations representative and or the management team.

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

7/13/2020

Med-X Management Team Begins Planning an IPO to Support and Bolster Growth Initiatives

In this important update, COO and President, Matthew Mills discusses a strategic plan to list the Company on a national exchange to support and bolster the growth of the Nature-Cide and the Thermal-Aid divisions. Matthew Mills also reports on exciting news regarding the Company’s revenue growth, progress with institutional investment firms and the status of the Nature-Cide toxicity testing. Please watch this important announcement. 

 

 

With the recipe of essential products and services, growing revenue, international distribution positioning, all while negotiating with a handful of investment banking firms, the management team has decided to move forward with the plan to execute an Initial Public Offering. 

In order for us to successfully execute this plan, we have to immediately accelerate our internal capital raising efforts to support our ongoing growth with continued inventory needs, our marketing initiative expenditures, supporting our stabilized overhead as well as the cost associated with the accounting and legal teams to position the Company for an IPO. All of this is needed to enable our market entrance in a timely manner. This is a call to action for every shareholder to get involved. We cannot stress enough the importance for all current shareholders to participate in any way they can, to help bridge the gap from a private company to a public entity. 

Many of our shareholders have expressed excitement in recent weeks, as our revenue for 2020 has broken out, while mid to large-sized investment banking and family offices show interest in an opportunity for sizable long term international positioning.  

With over 3000 shareholders that supported our growth thus far, we know, as a group, we can get this done together. This opportunity has come with a lot of hard work, of which our shareholders have supported the Company every step of the way.  We are very excited to have the continued support from everyone who has believed in this mission. It took a village to build this Company and besides having a nice growth spurt going for 2020, it's clear that the size of our investor base is another major attribute of interest to the investment banking community. That said, it's going to take OUR village to help steer, land and pass the baton to these large scale investors in the coming months to continue to fuel our growth potential long term. 

If you have questions about this plan of action and or want to learn more of the specifics, please contact our Investor Relations department.

Thank you very much for all of your continued and future support. 

Please Click the Invest Now Button

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the Regulation A+ Offering Circular and the New Regulation CF Offering as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

6/2/20

Med-X Launches Regulation CF Crowdfunding Offering on TruCrowd as it Continues to Grow as an Essential Supply Business

In this video update, COO, Matthew Mills, updates the company shareholders on the continued growth of the Nature-Cide Professional products as well as additional growth on Amazon from our Nature-Cide Ready to Use products. 

Matthew also announces the launch of an additional capital raising campaign, a Regulation CF Offering, that will offer new potential investors on the TruCrowd platform the opportunity to get involved. In addition, Matthew also discusses the recently filed 1-K Annual Report, progress with toxicity testing and the on-going efforts to bring on institutional investors to advance the company more rapidly. 

The Full Regulation CF Press Release can be seen at the end of this update.

 

If there is anything that we have learned through these challenging times, it is that our customers depend on us to keep supplying them. All of our main distributors are essential businesses themselves and they are supplying thousands of essential businesses all over the country. We are so thankful to all of our shareholders who have contributed in any way to help us keep working and keep inventory coming in to insure orders continue to meet the demand. We are cautiously optimistic about the growth we are seeing and we are confident that once the toxicity testing is officially completed, the interested parties from around the world can finally get products into position to meet their needs.  

In order to keep this momentum moving forward on all of these fronts, especially inventory and marketing for Nature-Cide and Thermal-Aid, the company has decided to open all capital raising opportunities and launch a Regulation CF Offering on the TruCrowd investment platform. This offering is separate from the Regulation A+ offering on Medxinvestor.com. Both offerings are now running simultaneously with the goal of reaching as many new potential investors as possible. The full press release can be read at the end of this update. 

Our accounting and finance team have been hard at work over the past month to complete our 1-K Annual SEC Filing just as the Covid-19 pandemic hit. The filing has been completed and our full 2019 audited financials are included in the filing and which is available to everyone on the Edgar platform. You can find that link at the end of this update. 

Selling and supplying products to essential businesses in pest control and pharmacies has allowed us to continue to grow this year even during the Covid-19 pandemic and economic stresses. Our major distributors like Target Specialty Products and Cardinal Health continue to order and supply their customers with our products. As of the time of this update posting the company is seeing a sizable increase in revenue year over year. Our marketing initiatives in 2018/2019 are paying off and our investment and focus on bringing the products direct to the consumer through Amazon has also brought the company a consistent lift in revenue month over month. We are seeing consistent sales direct to consumers from both brands as ecommerce grows and word of mouth spreads about our products with the public. 

Stillmeadow, Inc., the third-party laboratory who is conducting our Nature-Cide toxicity testing, is in the final stages of this work. We are confident that in the coming weeks the results will be back and we will finally be able to position Nature-Cide for worldwide markets. We are confident that this is going to open up a whole new door of new exciting opportunities in countries that have been waiting for months to get their hands on Nature-Cide professional use products. 

High-level discussions continue to happen with multiple institutional investment firms as they watch and strategize how to leverage our positioning, take the company to the market, offer our investors liquidity and more importantly how to infuse the company with large amounts of capital in order to expand the global footprint of the brands and position the company for long-term growth. 

These are exceptional unusual times we are all living in. We are all blessed to have a strong, well-positioned company that is selling into markets that need partners with reliable products and supply chains like Med-X, Inc. We owe all of this to the support of our staff and our shareholders who have believed in this mission from day one and continue to see the opportunities and possibilities as this company grows. We will continue to work hard and provide the professional pest control industry the green products it so desperately wants no matter how difficult the environment. 

Below are the links to 1-K Filing and the TruCrowd Campaign Page. Also please read the official press release below. 

Thanks for all of your continued support, be safe, and take care of one another. 

Link to Press Release: https://www.prnewswire.com/news-releases/med-x-inc-launches-regulation-crowdfunding-on-the-trucrowd-crowdfunding-portal-301065252.html

Link to K1 Filing: https://www.sec.gov/Archives/edgar/data/1620704/000147793220002917/medx_1k.htm

Link to TruCrowd Campaign: https://us.trucrowd.com/equity/offer-summary/Med-X

------

Med-X, Inc. Launches Regulation Crowdfunding on the TruCrowd Crowdfunding Portal

LOS ANGELES, May 26, 2020 /PRNewswire/ -- Med-X, Inc. -- On May 26, 2020 Med-X, Inc. announced the launch of a Regulation Crowdfunding campaign on the Crowdfunding portal TruCrowd.  Med-X is now hosting two separate crowdfunding initiatives to further bolster its progress and continue its year over year momentum. The new Med-X, Inc. Regulation CF is for one-million seventy thousand dollars ($1,070,000) while the Regulation A+ offering is for ten-million dollars ($10,000,000), on its own Regulation A+ platform, where the company has already raised over one-million dollars. The company has developed multiple natural product lines, including Nature-Cide and Thermal-Aid which are positioned in major national distribution, as well as its homeopathic lifestyle Malibu Brands, while becoming popular go to natural products amongst eco-minded professionals and consumers.

(PRNewsfoto/Med-X, Inc.)

About Nature-Cide:

Nature-Cide, provides our commercial and residential customers with all-natural, green, environmentally friendly and effective products via different applications for the control of insects while repelling rodents, reptiles and various birds.  The Nature-Cide product line was first implemented via our California licensed IPM (integrated pest management) service company "Nature-Cide Services." Nature-Cide products are now positioned in professional pest control, hospitality, janitorial and agriculture.  For more information, please visit https://nature-cide.com or email customerservice@nature-cide.com.

About Thermal-Aid:

Thermal-Aid is a division of Med-X, Inc.'s wholly owned subsidiary, Pacific Shore Holdings, Inc. based in Canoga Park, CA. Thermal-Aid products are used for pain management and help ease pain from arthritis and migraine headaches. The Thermal-Aid product lines are available online and at leading retailers throughout the United States.  For more information, visit: https://thermalaidproducts.com/

About Malibu Brands:

Malibu Brands is a premium, homeopathic lifestyle brand.  Malibu Brands' first product is the Pacific Pain Relief Cream, which is a proven, natural topical analgesic cream for the temporary relief of various pain issues including arthritis, joint, muscle, headache and migraine pain.  Malibu Brands is working to expand its product footprint with multiple products in development including a pain cream that utilizes Hemp/CBD as an ingredient.  Additionally, the Malibu Brands division is planning to embark on designing a unique clothing line that uses alternative sustainable materials such as hemp and bamboo, as they become more readily available.

ABOUT MED-X, INC. 

Med-X, Inc. is a Nevada corporation formed in February 2014 to support the fast-paced environmentally friendly green scene products and services sectors, with its Nature-Cide, Thermal-Aid and Malibu Brands divisions as well as the emerging hemp and cannabis industry through such activities as compound identification and extraction of the identified cannabidiol (CBD) compounds for the present medical industry demand. The company's digital magazine, The Marijuana Times, publishes high quality media content for the medical cannabis community to potentially generate revenue from advertisers as well as sell industry related merchandise to consumers. For more information regarding Med-X, Inc., please visit www.medx-rx.com, email info@medx-rx.com or call 818-349-2870.

----

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the Regulation A+ Offering Circular and the New Regulation CF Offering as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

4/30/20

To our Shareholders,

In response to the COVID-19 pandemic, we want to share that our focus is on continuing to keep our shareholders informed. In that regard, the Securities and Exchange Commission (“SEC”) earlier this month announced that due to the impact of COVID-19 on businesses, it was providing Regulation A+ companies a 45-day extension to file its Form 1-K Annual Report. Because Med-X personnel and audit personnel are now working remotely as much as possible and relying on our staff to scan and email work papers and other documents, the Company’s ability to complete its audit and file the 2019 Form 1-K prior to its due date is delayed.  Notwithstanding the foregoing, the Company expects to file the 2019 Form 1-K shortly but no later than June 13, 2020 (which is 45 days from the 2019 Form 1-K’s original filing deadline of April 29, 2020).

4/21/20

As an Essential Business,  Med-X Keeps Fulfilling Orders and Continues to Service Customers

In this update video, President and COO, Matthew Mills, discusses how the company has managed to keep generating revenue during the current California and Los Angeles County Stay-at-Home order, by continuing to fulfill essential business demands.

 

Nature-Cide and Thermal-Aid continue to see a steady amount of orders going out to our multiple distribution partners, as well as facilitating consumers directly via our Amazon FBA positions.

A new opportunity has also presented itself during these disruptive times. As of April 3rd, 2020 the State of California has made it possible for all QAL license holders in pest control operations to now also conduct sanitization services. We already own all the essential equipment and gear to properly enter this market on the service side all in all-natural applications. This will widen the Nature-Cide service offerings and open the door from more revenue on the expanding service side of the business. 

We have recently had several discussions with the team from the Journal of Florida Mosquito Control Association. We plan to supply as many products as they need to continue testing Nature-Cide products, including the impact of the product on pollinators and aquatic life. These third-party field tests help us and other pest control operators truly understand how to use our products and how powerful they are when going head to head with the top synthetic brands. 

Toxicity testing for Nature-Cide concentrated liquids is now underway. We have engaged with a laboratory called, Stillmeadow. Testing is being conducted on the All-Purpose Concentrate and the Pest Management X2 Concentrate. The ETA on the results of this testing will be the end of May. The purpose of this testing is to provide our international customers with the necessary completed toxicity protocols which are needed to import these products into various countries. This is going to open the door to most of the international markets that require toxicity testing to import all pesticide products. 

Over the past few months, the company has also been working to build its catalog of products under the Malibu Brands division. We are well-positioned and prepared to start manufacturing small runs of a variety of CBD products including a line of pet products. Once our inventory starts to grow we will be presenting these products to our OTC distributors in hopes of eventually positioning with our OTC pharmacy footprint that we already have in place with our Thermal-Aid division. 

Revenue for Q1 of 2020 is beating our initial projections at this point for the year. This is a 190% growth from this same time in 2019. In the video, Matthew showcases a chart showing this revenue comparison. 

We cannot thank all of the shareholders enough, especially the folks who have stepped up to help us get the Toxicity testing underway and making sure we stayed our ground during this turbulent time.  

We will continue to stay positive while taking advantage of all the opportunities that continue to present themselves. 

Again, thank you for all of your support and stay tuned for more updates. 

Be safe and take care.

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

3/19/20

Company Positioned to Sustain Revenue During Covid-19 Pandemic

In this update COO, Matthew Mills informs the company shareholders that the company has taken the necessary steps and guidance to protect the team members who are working to fulfill orders that continue to come in.

 

Our entire team is safe and we are prepared to do whatever is necessary to protect the company's assets and support the needs of our customers and the community. Seemingly our products continue to carry a popular position, even in difficult times.

We can’t thank you enough for your support. The management team is very confident that once we get through these challenging months ahead, our company will be in a perfect position to capitalize on our strategy and continue to grow this business by expanding our products, services, and divisions. 

We ask all of our shareholders to please take this National Emergency seriously. We are located in Los Angeles County, a hot spot for the spread of the Covid-19 virus. We cannot thank our community leaders, healthcare workers and the citizens of the Los Angeles County area for recognizing the seriousness of this issue, and everyone doing their part. Wherever you live, please take all the necessary precautions to keep yourself and your family safe.

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

2/13/20

$1,000,000 Raised Milestone Reached on the New Offering

In this update, President & COO, Matthew Mills announces the Company has reached its first crowdfunding capital raising milestone of $1,000,000. He also gives us an update on the acquisition front as well as an important request.

 

The $1,000,000 milestone on any crowdfunding offering is always something to celebrate!!  🙏🎉🎊🎈

We are grateful for all of the shareholders who have participated in the Med-X offerings and excited to see what 2020 has brought so far. We certainly couldn't be seeing brand growth along with green philosophy approaches, that our professional use and consumer customers are practicing daily, without our amazing shareholder’s support! 

As the management of Med-X, Inc., it is our mission to create as much value as possible for the Company, its shareholders, employees, and the community. All of us recognize the power of networking. It is time for us to now leverage our power as a large group of shareholders and professionals.

That said, if you have not already signed up yet to the National Investor Network, please get involved and participate. This media platform is going to be a solid element for our future growth as a Company, and we want all shareholders to have the opportunity to be involved. Therefore, we need everyone’s participation by enrolling in the National Investor Network. It only takes a minute of your time to sign up. 

Go to www.nationalinvestornetwork.com.

Click the Green “Sign Up” button and fill out the form.  From there a confirmation email will be sent to you. Please go to your email and wait for the confirmation email to arrive. When it does, please confirm your sign up. 

We are building a one of a kind robust investment resource and database that is already growing its membership. As it grows, so will its programming and reach allowing us to tap into the evolving tech investment space long term. 

Thank you for all of your support,

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

01/17/20

Two Year Independent Study in Florida Finds Nature-Cide as the Top Performing Pesticide in a Side-by-Side Study Against Top Selling Synthetic Products in Laboratory and Field Analysis for Mosquito Control

It has been a very busy month so far here in Los Angeles. We have a lot to cover and it is important that all shareholders receive this information. 

In this video update, Matthew brings us up to speed on developments to date in January 2020. 

Some of the topics Matthew touches on in the video are:

  • Status of the Custom Bed Bug Acquisition.

  • Announcement of Nature-Cide making the shortlist of approved pesticides for the cultivation of industrial hemp in the state of Kentucky. 

  • A statement that production begins on CBD Formulation of the Malibu Brands Pacific Pain Relief Cream. 

  • The introduction of Bugly, the first at-home retail membership for an all-natural “Do It Yourself” pest control program, that is a private label partnership with Nature-Cide.

  • Journal of the Florida Mosquito Control Association published a study showing the results of a two-year comprehensive study testing the efficacy of 25(b) products alongside the top three global pyrethroid products. The results are astonishing. 

  • Status of the pesticide toxicology testing overview. 

  • Review of product retail positions and status update on the 2020 inventory needs for all retail brands. 

  • Statement regarding Glendale Securities' position with the Company in preparation for the next steps after the potential acquisition. 

  • Status of moving the Reg. A+ offering away from StartEngine onto our own independent platform and the launch of a new Regulation Crowdfunding Offering that will be run and overseen by the StartEngine Broker-Dealer Division and run on their platform. 

 

Update: 

It has been a busy and productive start to the year for the Company. Again, we are thankful and very appreciative for all of your support and attention. Our Management expects to accelerate the Company with both product and service revenue goals while raising the capital needed to potentially position the Company to engage with the Investment Banking community and potentially list the Company on a national exchange. Everyone is working harder than ever to continue the expansion of the Company, as well as find liquidity for our shareholders in both the short and long term. We are hopeful that all of you are just as excited as all of the Med-X staff members and will continue to support our mission in the efforts of making a difference everyday and sharing our work with family and friends to help the cause move forward in a more rapid manner. 

Acquisition Strategy

The Custom Bed Bug acquisition is not finalized but it is close. Legal is tying up the loose ends on both sides. These things take time and we are grateful for all the hard work that has gone into this on both sides. Anything can happen with these things, and the deal won’t officially be done until we announce it. Once this is finalized we will be moving swiftly to start the talks with our other targets who are standing by waiting for engagement. This is the service piece of the business that the investment bankers that we are speaking with, are waiting for Med-X to finalize. 

Hemp Farming

We are excited to announce that the Kentucky Department of Agriculture has listed both the Nature-Cide All Purpose Concentrate and the Nature-Cide Outdoor as approved registered products for the cultivation of industrial hemp. This again solidifies our national position in the Cannabis and Hemp markets as a leading insecticide solution. Kentucky is a leading producer in US Industrial hemp and we see this as the important list to be on as other states follow Kentucky’s lead in regulating hemp farming in the US. We also believe that the Kentucky regulatory system will also be considered when, and if, the Federal Government opens the doors to THC cultivations with the seemingly imminent descheduling of Marijuana from the Controlled Substance Act. 

Click Here to Download the Kentucky Department of Agriculture Document

Malibu Brands

We are in multiple discussions with local contract manufacturing partners in regard to the mass production of the Malibu Brands products. This also includes the official launch of the Pacific Pain Relief Cream with added CBD. The Management team is in talks with several financial institutions who will potentially become critical partners for us as we begin to sell the Hemp-derived CBD products. The Company is also working diligently to get both the CBD Pain Relief Cream and the Non-CBD Pain Relief Cream registered with the FDA. This is a long process but if and when we are able to finalize this, we are confident our Healthcare Distribution partners will begin taking on that line of products as well placing the products into OTC pharmacies. 

Nature-Cide Breakout to Retail

We are also proud to announce our partnership with the team from Bugly, the first at-home retail membership for an all-natural “Do It Yourself” pest control program, that is a private label partnership with Nature-Cide. The Bugly project will be our first major step to provide the products directly to the consumer. We have to be strategic on how we enter the retail market as to not disrupt our positions in Professional Sectors. We believe this approach and this model have a great chance to be very successful. The model is seeing success in other DIY products like lawn care and we are excited to see how it performs as the insect season picks up. 

Nature-Cide Mosquito Efficacy

The Nature-Cide products have a great deal of efficacy to back up their claims and as a multi-state registered pesticide, we are forced to prove certain efficacy in order to get our labels registered. These products have been tested by professors and scientists on several occasions. But when we were recently informed about the latest findings from a two-year report published in the latest journal of the Florida Mosquito Control Association, we nearly fell out of our chairs. We knew the Nature-Cide products performed well on mosquitoes but we were thrilled to read that Nature-Cide was found to be the top-performing mosquito insecticide tested, regardless of its botanical status. Globally the fight to control mosquitos is the top public health priority with 17% of all infectious diseases transmitted globally are vector-borne. Mosquito vector control is the holy grail of pest control. Mosquito vector control is typically the responsibility of local, county, regional and federal municipalities. The scope and importance and potential implications of this study are not yet fully set in with the management team. The products hands down blew away our top green competitor “Essential IC3” and also outperformed, at all mixture rates, all of the top three biggest global sellers of synthetic pyrethroid mosquito insecticides. This was a third party scientific study done without our knowledge and it deserves everyone’s close attention. Please read the report. Below are the abstracts from both of the individual studies using both formulations. 

The trouble with Controlling Mosquitoes is the balancing act you have with the risk of spraying the chemicals. The chemicals can only be sprayed so much or else the risk of poisoning and polluting the environment become too high. With a 25(b) botanical products like Nature-Cide, you can apply the product freely with little to no risk of environmental and human contamination. This could be the break we have been waiting for. The last step is to finalize the findings with toxicology reports to confirm that the products do not pose a risk to water ecology and non-target pests like pollinators. 

Below we have included the Abstracts from the report and we highly suggest you download the full report and reviews, to see the results and the positive comments for yourself. 

Download the Full Report Here

 

EVALUATION OF PYRETHROID AND BOTANICAL BARRIER INSECTICIDES AGAINST AEDES ALBOPICTUS IN THE LABORATORY AND FIELD

STEVEN T. SMOLEROFF, CHRISTOPHER S. BIBBS, AND RUI-DE XUE

Anastasia Mosquito Control District, 120 EOC Drive, St. Augustine, FL 32092

Subject Editor: Seth Britch

ABSTRACT

Outdoor residual insecticide applications are useful for preventing or reducing mosquito populations at focal areas. Until recently, pyrethroids have been the only option for barrier sprays in mosquito control. In this study, three pyrethroid (Onslaught, Cyzmic CS, DeltaGard) and two botanical (Nature-Cide, Essentria IC3) outdoor residual insecticides were comparatively tested at low, mid, and high label rates against adult Aedes albopictus in both laboratory bioassays and field trials in St. Augustine, FL, from May-August 2017. Bioassays indicated NatureCide and Cyzmic CS were the most toxic across all three dilution ratios followed by DeltaGard, Onslaught, and Essentria IC3, respectively. In field trials Nature-Cide and Onslaught were the only products that reduced mosquito abundance at the low rate. However, at the mid rate Nature-Cide and Onslaught caused ~90% percent reduction of adult female Ae. albopictus in the field, the highest of all tested products. The performance of DeltaGard (79% reduction in field counts), Essentria IC3 (64%), and Cyzmic CS (36%) in the field were not similar to the laboratory results. The universally high performance of Nature-Cide indicates that mosquito control operations should expand consideration to botanical based insecticides for field operations.

 

SEMI-FIELD ULV EVALUATION OF AN ALL-PURPOSE BOTANICAL INSECTICIDE CONTAINING CEDARWOOD AND CINNAMON OILS AGAINST ADULT AEDES AEGYPTI

CHRISTOPHER S. BIBBS, KATHY SHIRLEY, DENA L. AUTRY, AND RUI-DE XUE

Anastasia Mosquito Control District, 120 EOC Drive, St. Augustine, FL 32092

Subject editor: Eva Buckner

ABSTRACT

Public health mosquito control operates with only two classes of mosquito adulticides: pyrethroids and organophosphates. Recent work improving the emulsification of essential oils has increased the potential for development of plant derived active ingredients. There is a growing body of literature on essential oils for various roles in mosquito management. Nature-Cide Pest Management (NCPM), a product available in private and commercial home pest control, uses a mixture of 25.3% cedarwood oil and 12.7% cinnamon oil as a Federal Insecticide, Fungicide, Rodenticide Act (FIFRA) exempt insecticide for both indoor and outdoor use. Recent investigations by the Anastasia Mosquito Control District of St. Johns County have found other FIFRA exempt products to be effective as a residual spray on vegetation. In continuing the exploration of botanical insecticides, NCPM was used in ultra-low volume (“ULV”) tests against Aedes aegypti (L.) within its 35-122 ml per L of water label rate. Applications at 35 ml/L resulted in 60-70% knockdown after 1 hr and mortality after 24 hr. Increasing the rate to 70 ml/L resulted in 100% knockdown and mortality across all replications. Crystalline precipitation of the microemulsion was observed in mix tanks after standing for at least 2 wk, but it was not apparent that the efficacy of the product was reduced as a consequence. Cedarwood oil and cinnamon oil are a beneficial combination for ULV adulticiding against mosquitoes and could have a beneficial role for integrated mosquito management.

Retail Inventory

Purchase Orders are already starting to roll in for Thermal-Aid and Nature-Cide. With word of the report about Nature-Cide starting to spread in social media, we need to make sure our inventory levels are adequate to fulfill these growing pains. Everything is seemingly ramping up across the board and we are going to need to keep up with the demand of positioning our high margin products over the next few months. 

Toxicology Reports

Several countries have been knocking on the door for months waiting for the Nature-Cide Toxicology reports. When the reports are completed, we will begin engagements and enter most of the other countries to continue the growth of the Nature-Cide brand world-wide. These reports are costly and require all of our focus to get this down, as we believe the rewards to be very beneficial for the Company. The need for the Nature-Cide products is much stronger overseas than in the US. Pesticide regulations are far more strict in all other countries vs. the US. The sooner we can complete the toxicology studies, the faster these products can go to Southeast Asia, Africa and South America where the governments of these countries spend hundreds of millions of dollars spraying toxic chemicals to maintain public health requirements on mosquito control and pest management. 

Listing

Glendale Securities has delivered the 15c2-11 information requirement package and we have several investment banks sitting on the sidelines waiting patiently for the Custom Bed Bug acquisition to be finalized. As soon as we hit our revenue milestones and have the capital on hand with a commitment from an Investment Bank, we plan to pull the trigger and list on an exchange when the timing is right and the market conditions are favorable. 

Crowdfunding Platforms

Very soon the Company will be pulling its Reg. A+ Offering off of the StartEgine platform and replacing it with a Regulation Crowdfunding Offering (“Reg CF”). We are doing this to fulfill our commitment to our broker-dealer NMS Capital and to allow ourselves the flexibility needed to go out and continue raising capital, with multiple Broker-Dealers by our side. This is the best move for the Company at this time. We are hopeful that the technology we have built for our new capital-raising platform will offer our investor relations and marketing team the transparency and flexibility needed to raise the capital rapidly that the Company needs. The Reg CF will still allow individuals who prefer the StartEngine Platform to continue to invest. However, moving forward in the coming days, all new Reg A+ investments will be processed via our new, independent platform on medxinvestor.com.  

As you can see, there are a lot of great things going on here at the Company, and we are confident in the direction we are headed. We need every staff member, associate and shareholders’ focus to share our mission of making a difference every day with friends and family so as to expand the work we are doing world-wide. 

I cannot thank each and every shareholder enough. We want to hear from you directly. If you have ideas or know people in states that can help our efforts, please call us. Together we can continue making a difference every day. 

 

Sincerely, 

Matthew Mills

 

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

12/30/19

2019 Year-End Review and Outlook for 2020

Happy New Year! As we close out the end of this amazing year I wanted to take some time and reflect back on a few important milestones the company was able to accomplish in 2019 and then cover some important items as we start 2020. It was a very productive year and we are set up nicely to have an even more productive year in 2020.

A year in review:

  • Nature-Cide products were introduced and sold to the professional turf grass industry for the first time.
  • Nature-Cide’s international footprint grew with Rentokil in several new countries.
  • Nature-Cide committed to a larger strategic marketing plan with the largest pest control distributors and industry publications.    
  • The company launched its Acquisition Company Roll-Up Strategy and entered into talks with several targets in the pest control service arena. 
  • The company signed a letter of intent and is working to close its first pest control service acquisition.  
  • The company reserved the Nasdaq Symbol “MXRX”.
  • Malibu Brands Pacific Pain Relief Cream was launched. 
  • The company successfully closed its first Regulation A+ offering on StartEngine in June of 2019 capping the round off in the neighborhood of $7 million raised since 2016.
  • The company signed with broker-dealer NMS Capital to partner on its new Regulation A+ capital raise. 
  • The company launched the National Investor Network. 
  • The Marijuana Times helped break the story on contaminated cannabis oil being sold on the black market. 
  • Thermal-Aid products saw growth from Cardinal Health Distribution and direct-to-consumers.
  • Nature-Cide delivered hundreds of samples of products to professionals in 2019 as the word spread around the world.  
  • The company launched its own investment platform for its new Regulation A+ offering.
  • The company surpassed its 2018 revenue in Q4 and reached its 2019 revenue goals. 

It was a challenging but satisfying year for our company. All of the support from our shareholders and partners allowed us to keep this movement going in a positive direction. The brands themselves, especially Nature-Cide, has become globally known as a premier Green Pest Control product line.

2020 is going to require everyone at the company to work harder than they have ever worked. This is the year where we pick up where we left off with direct-to-consumer sales for Thermal-Aid and explore a consumer revenue stream with Nature-Cide for the first time. Our media divisions are positioned to continue to grow especially the National Investor Network. The Equity Crowdfunding Report is already quickly positioning itself as the only media outlet using video to specifically cover the Equity Crowdfunding Markets and new private equity investors are learning about its resources. International pesticide label registration processes for many major countries are underway and we hope for this long process to be completed in 2020 opening the international flood gates for Nature-Cide. Conversations continue with our largest OTC healthcare distributor, Cardinal Health, to increase the footprint of the Thermal-Aid products as well as the introduction of the Malibu Brands Pacific Pain Relief Cream into OTC pharmacies. The company roll-up strategy is scheduled to go into overdrive as our first acquisition wraps up in legal and hopefully it will be announced in early 2020. We have several targets waiting in the wings to see how this first acquisition goes and we are hopeful other like-minded companies are going to want to be a part of this movement. NMS Capital is dedicated to continuing to support our efforts to bring in institutional partners into the mix as we continue our commitment to a listing on a national exchange when the time is appropriate. 

Without the continued support from each and every one of our shareholders we could not have made the progress we did this year. We all look forward to continuing the GREEN movement in these industries that are truly being forced to accept the changes coming. Natural products and services will have a place at the table in 2020 and many years beyond. 

The management team is committed to continuing to keep all of our shareholders apprised and updated on a regular basis, and in 2020 the team will continue to make ourselves available to all of our shareholders anytime. 

I wrapped up the year with an interview with our Chief Media Officer, Nick Philips, on the Equity Crowdfunding Report. It is a long, comprehensive interview. If you are interested in hearing more about 2019 and 2020, we cover many topics in the interview. We are all excited about the show and the buzz it is generating in the equity crowdfunding world. You can watch it by signing up, or logging in if you are already a member of the National Investor Network

Happy New Year!

Sincerely, 

Matthew Mills

President & COO

 

VIDEO INTERVIEW BELOW

Matthew Mills Interview

11/7/19

Med-X, Inc. Surpasses 2018 Revenue During the 4th Quarter of 2019 While in Final Stages of it’s First Pest Control Service Acquisition

In this update, Matthew reports on how 2019 revenues have already surpassed 2018 revenues across multiple divisions as well as how its potential acquisition could lead to engagements with large scale investors. This progress has motivated Med-X Management to prepare the company accordingly, as they meet with the potential sponsors to list the company.

Our largest Over The Counter or “OTC”  Pharmacy distributor Cardinal Health / RGH just placed an order to continue to distribute the Thermal-Aid product line throughout “OTC” pharmacies which are performing well and selling-through. We anticipate these orders to continue to increase in frequency and volume.

This kind of traction coupled with our direct to consumer boost through Amazon, is forcing us to quickly ramp up our production for this line as PO’s from our distributors continue to get larger and inventory requirements from Amazon Fulfillment continue to increase and seemingly are snowballing. We need to be ready for 2020 because at these rates it is going to be a busy start to the year.

We feel strongly that with all of this increased visibility and with these high sell-through rates it is only a matter of time before the bigger “OTC” retail players jump on board and begin to load the products as well, so we need to be ready!

Conversations have also continued to ramp up with many overseas pest control operation distributors. We are in talks with companies from Canada, Mexico, Indonesia, Nicaragua, Brazil, Peru, Australia, Saudi Arabia, Dubai, Bahrain, South Africa, United Kingdom, New Zealand, Malaysia, the Philippines, and South Korea. Governments in these countries continue to tighten regulations on the use of pesticides and these distributors are scrambling to get new products in place that will pass their toxicity and environmental impact requirements.

The importation of pesticides into foreign countries requires the company to comply with each countries stringent regulatory red tape. We are working to have the Nature-Cide products fully scrutinized and registered in all of these countries. Once the studies are done we will be able to register our products on an individual basis with each country, all of which have their own requirements and processes that require the above-mentioned testing to be completed. This is an incredibly important time for our company to buckle down and invest as much of our resources as possible in getting the Nature-Cide products positioned accordingly. Once this is accomplished, Nature-Cide products and protocols could very well end up leading the all-natural global pest control markets. 

The company is also in the final stages of an acquisition of a pest control service company that is doing over $1M annually in service revenue.

With this acquisition, our plan is to significantly increase revenue in 2020 compared to 2019 starting in Q1. We are all hopeful and waiting patiently for the legal teams to finalize agreements, so the company can make the acquisition official.  We are also hopeful that several other acquisition targets will fall into line once the first transaction is complete, and word continues to spread that we are actively acquiring like-minded pest control companies.

The revenue growth and acquisition plans have various large scale investment funds watching the company very closely, and we are excited to have the opportunity to present our work accordingly. This said we are meeting with an interested sponsor in the coming days to discuss the process of a 15c2-11 filing which is the first step in the potential listing of the company. The goal is to organize and engage with the perfect financial partner to support our growth and acquisition plans, then expand further if and when we list in a public marketplace.   

The team is dedicated to working harder than ever in the final weeks of 2019, in order to make sure the company continues to grow and we begin 2020 in the best shape we have ever been in. We are all excited to see what the future holds.

Matthew is available to discuss the growth of the company one-on-one, so don't hesitate to reach out and schedule an appointment.

 

Thank you for all of your continued support.

Nick Phillips

Med-X Team

 

DISCLAIMER AND FORWARD-LOOKING STATEMENTS

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company.

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

 

10/17/2019

Nature-Cide Shines at PestWorld 2019

In this update, COO, Matthew Mills reports from the TradeShow floor at PestWorld 2019.

At the show, the team has been meeting with hundreds of business owners who are all interested in learning more about adding green options to their product offerings. Owners of pest control companies from all over the world have all met in one place to get educated and to network. “We have been doing this show for a few years now and this year is by far the most attention we have had around the company,” says Matthew Mills. “When we first started doing this a few years ago people would come up to us and not recognize the need for green pest control products, as well as believing that Nature-Cide couldn’t possibly be a viable solution. Now the word has spread and people from all over the country and the world are waiting in line to talk to us. The market is changing really fast. Those same people are coming back to learn more because their customers are asking for green options. We are in a really great place,” says Matthew. 

The show is known worldwide as the premier pest control tradeshow and with that comes numerous face to face meetings with international companies that we typically don’t get much face time with. Today, Matthew met with several large scale pest control company owners who want the Nature-Cide products in their countries. He met with leadership from companies in several strong and emerging markets but more significant and important were the meetings with companies in Malaysia, Brazil, and Korea as we have been in communication with them for weeks. It is always very nice to put faces to names. We walked away with some very positive takeaways and solid commitments to work together with multiple international regulatory bodies to get the Nature-Cide products registered for usage within the various countries.

We had multiple investment banking groups who have had their eyes on us and decided to come down and see the attention we were generating first hand. These groups are going to continue to dig in as it appears that they like the company’s positioning, especially on the Nature-Cide front. The continued hope is we find more institutional partners who are trying to diversify by investing in environmentally friendly companies.  

Matthew had several important meetings with the leadership teams from our Distribution partners at Target-Specialty Products and Univar. It is critical that these relationships continue not only to be beneficial to all parties but to also flourish in 2020. The distributors have again given us their word that they will continue to push our products as one of the top-performing effective natural product lines. These multi-billion-dollar businesses see the green wave coming and they want to be a part of it.   

We also locked down some commitments on the retail side of things. We cannot fully disclose all the details yet, but we are hopeful that this relationship will be very fruitful. So stay tuned for that announcement in the coming weeks. 

This truly is a very exciting time for Med-X, Inc. We have a solid position in several markets with proprietary products and solutions that have a great upside in markets that need new life. 

Without each and every investor’s focus, we could not continue to grow. We appreciate all of your support. 

If you want to speak directly with Matthew and hear more about the events that took place at the show, please reach out to our investor relations department so we can put something on the books. If you do not have a point of contact yet, please let us know and someone will follow up accordingly. 

 

Nick Phillips

Med-X Team

 

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

9/24/2019

Strict International Regulations on Pesticides Continue to Fuel Nature-Cide Expansion and Growth Outlook

In this update, COO, Matthew Mills takes you inside the Med-X facility for a look at the day's preparations for several existing customers and a few new international Nature-Cide orders. The international interest in Nature-Cide is a clear indicator of the growing trend of the professional pesticide industry moving to include safer green options.

 

 

The team is making final preparations for what we hope to be our most important and successful appearance at the largest pest control trade show in the world, PestWorld 2019. This year’s trade show is taking place in San Diego from October 15th to October 18th. If you want to meet with Matthew Mills and see the action for yourself let us know so we can make arrangements in advance for your visit. Our distributors are all excited to showcase the Nature-Cide brand and we would love the opportunity for any shareholder to actually see the excitement around Nature-Cide in the broad scope of the international community.

Matthew and the management team is also focused on providing updates more frequently as we move forward. Our commitment to providing reliable communications to our shareholders is critical. Expect a few more very important updates coming down the pipeline in the next couple of weeks leading up to Pestworld and post trade show.

Thanks for your continued support,

Nick Phillips
Med-X, Inc.

DISCLAIMER AND FORWARD-LOOKING STATEMENTS

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company.

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.